<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854447</url>
  </required_header>
  <id_info>
    <org_study_id>2.68/27-02-2019</org_study_id>
    <nct_id>NCT04854447</nct_id>
  </id_info>
  <brief_title>Part-time Versus Full-time Spectacles for Myopia Control (ParMA Study)</brief_title>
  <official_title>Part-time Versus Full-time Spectacles for Myopia Control (ParMA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>State Scholarships Foundation (IKY)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the effect of part-time compared to full-time spectacle use in&#xD;
      juvenile myopia control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, controlled clinical trial was designed for assessing the effect of&#xD;
      single-vision spectacles on myopic progression. 30 myopic subjects, aged 6-16 years old, with&#xD;
      a spherical equivalent refraction between -0.50D and -6.00D, were recruited. A random number&#xD;
      table was used to allocate participants into either a) part-time use of single-vision&#xD;
      spectacles, or b) full-time use of single-vision spectacles. Part-time use was for 4-6 hours&#xD;
      a day, 7 days a week for a year. Clinical assessment included follow-up at 6 months and at 12&#xD;
      months upon allocation. The primary outcomes were a) change in spherical equivalent&#xD;
      refraction (SER) measured by cycloplegic autorefraction, and b) change in axial eye length&#xD;
      (AL). The secondary outcomes were a) change in choroidal thickness (ChT), and b) assessment&#xD;
      of the subjective tolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">June 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in spherical equivalent refractive error (SER), measured using cycloplegic autorefraction.</measure>
    <time_frame>Baseline to 6-months, and baseline to 12-months.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in axial length (AL).</measure>
    <time_frame>Baseline to 6-months, and baseline to 12-months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in choroidal thickness (ChT).</measure>
    <time_frame>Baseline to 6-months, and baseline to 12-months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective tolerance, as assessed using a standardized questionnaire created for the purpose of this study.</measure>
    <time_frame>Baseline to 12-months.</time_frame>
    <description>This questionnaire is formed by the researchers participating in this study and is aimed at providing a qualitative assessment of the subjective tolerance of included children wearing spectacles. It incorporates 6 questions and is not based on a scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part-time myopia correction with single-vision spectacles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Full-time myopia correction with single-vision spectacles</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Single-Vision Spectacles</intervention_name>
    <description>Spectacle correction for myopia treatment</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 4 to 16 years old at the time of enrollment.&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) LogMAR 0.1 or better, in each eye.&#xD;
&#xD;
          -  Cycloplegic Autorefraction: Myopia, SER between -0.50D and -6.00D, in each eye.&#xD;
             Astigmatism less than or equal to 1.50D, in each eye. Anisometropia less than or equal&#xD;
             to 1.50D between the two eyes.&#xD;
&#xD;
          -  Absence of any ocular or systemic condition that could influence refractive&#xD;
             development, other than myopia.&#xD;
&#xD;
          -  Eagerness to participate in this study and receive myopia treatment in a randomized&#xD;
             fashion. Availability for at least 1-year follow-up. Subject parent's or guardian's&#xD;
             understanding of the protocol and acceptance to participate, providing a signed&#xD;
             consent on behalf of the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of strabismus.&#xD;
&#xD;
          -  Presence of amblyopia.&#xD;
&#xD;
          -  Prematurity (gestational age less than 37 weeks).&#xD;
&#xD;
          -  Presence of an ocular condition affecting refraction (ie. cataract, dislocated lens).&#xD;
&#xD;
          -  Presence of a systemic condition affecting refraction (ie. Down syndrome, Marfan&#xD;
             syndrome).&#xD;
&#xD;
          -  Allergy to cyclopentolate. Severe ocular or systemic allergies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>&quot;Papageorpiou&quot; General Hospital</name>
      <address>
        <city>Thessalon√≠ki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Vasudevan B, Esposito C, Peterson C, Coronado C, Ciuffreda KJ. Under-correction of human myopia--is it myopigenic?: a retrospective analysis of clinical refraction data. J Optom. 2014 Jul-Sep;7(3):147-52. doi: 10.1016/j.optom.2013.12.007. Epub 2014 May 10.</citation>
    <PMID>25000870</PMID>
  </reference>
  <reference>
    <citation>Sun YY, Li SM, Li SY, Kang MT, Liu LR, Meng B, Zhang FJ, Millodot M, Wang N. Effect of uncorrection versus full correction on myopia progression in 12-year-old children. Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):189-195. doi: 10.1007/s00417-016-3529-1. Epub 2016 Oct 29.</citation>
    <PMID>27796670</PMID>
  </reference>
  <reference>
    <citation>Logan NS, Wolffsohn JS. Role of un-correction, under-correction and over-correction of myopia as a strategy for slowing myopic progression. Clin Exp Optom. 2020 Mar;103(2):133-137. doi: 10.1111/cxo.12978. Epub 2019 Dec 18.</citation>
    <PMID>31854025</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Asimina Mataftsi</investigator_full_name>
    <investigator_title>Associate Professor in Ophthalmology, Paediatric Ophthalmology and Strabismus</investigator_title>
  </responsible_party>
  <keyword>Myopia</keyword>
  <keyword>Spectacles</keyword>
  <keyword>Full-time correction</keyword>
  <keyword>Part-time correction</keyword>
  <keyword>Childhood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

